Journal
JOURNAL OF DERMATOLOGY
Volume 50, Issue 4, Pages 561-564Publisher
WILEY
DOI: 10.1111/1346-8138.16668
Keywords
autoimmune blistering disease; bullous pemphigoid; remission; rituximab; ultra-low dose
Categories
Ask authors/readers for more resources
Three cases of refractory bullous pemphigoid were successfully treated with ultra-low-dose rituximab (100 mg weekly for 4 weeks), confirming its efficacy and positive outcomes. The ultra-low-dose rituximab regimen may serve as a useful alternative therapy for refractory bullous pemphigoid patients.
Rituximab has proven effective for the treatment of steroid-refractory bullous pemphigoid (BP), but there is controversy over the dosing protocol. We report three cases of refractory BP treated successfully with ultra-low-dose rituximab (100 mg weekly for 4 weeks). Our cases confirmed the efficacy and good follow-up outcomes of this treatment strategy for refractory BP. The ultra-low-dose rituximab regimen (100 mg weekly for 4 weeks) may be a useful alternative therapy in patients with refractory BP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available